Tonix Pharma ( (TNXP) ) has issued an announcement.
Tonix Pharmaceuticals Holding Corp. has brought on Thomas Englese as the new Executive Vice President of Commercial Operations, signaling a strategic move in strengthening their leadership team. Additionally, the company announced a revised timeline for their New Drug Application submission for TNX-102 SL, a fibromyalgia treatment, now expected in October 2024. This development signifies potential growth and progress in the company’s product pipeline, of interest to investors watching the pharmaceutical sector for upcoming market opportunities.
Learn more about TNXP stock on TipRanks’ Stock Analysis page.
